Clinical trials: Liver Transplant Recipient
Transplant;Failure,Kidney, Transplant; Failure, Heart
EASE-SOT Pilot Study
Many transplant recipients may experience physical and emotional symptoms, such as anxiety, fatigue, sleep problems, pain, etc. Often, these symptoms are not reported or managed well, and can affect a patient's quality-of-life.
- Conditions
- Transplant;Failure,Kidney, Transplant; Failure, Heart, Transplant; Failure, Liver, Transplant; Failure, Pancreas
- Trial name
- NCT06396702
- Testing
- EASE-SOT
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
Recurrent Hepatitis C
Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection
This study will assess the efficacy of everolimus as an inhibitor of fibrosis progression in liver transplant patients who have a recurrence of hepatitis C viral infection in the transplant
- Trial name
- REVERT (NCT00582738)
- Testing
- CsA-TAC (standard Treatment), Everolimus
- Where
- Argentina
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Liver Transplantation, Immunosuppression
Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations
This is a randomized open label study in de novo liver transplant recipients that aims to compare the risk of tacrolimus induced tremors with once daily extended-release formulation, Envarsus, versus the twice daily…
- Conditions
- Liver Transplantation, Immunosuppression, Neurotoxicity, Tremor
- Trial name
- LCP-TAC (NCT05089604)
- Testing
- Tacrolimus, Immediate Release, Oral, Tacrolimus Extended Release Oral Tablet
- Where
- Canada
- Volunteers
- 124 people
- Sponsor
- University of British Columbia
Vaccine Hesitancy
Investigation on the Hesitancy of COVID-19 Vaccination Among Liver Transplant Recipients in China
On WeChat platform, through a point-to-point connection, and carry on the questionnaire survey to collect information of liver transplant recipients followed-up by the department of Liver Surgery, Renji Hospital Shanghai Jiao…
- Trial name
- NCT05532592
- Testing
- Perceptions and attitudes towards COVID-19 and COVID-19 vaccine
- Where
- China
- Volunteers
- 449 people
- Sponsor
- RenJi Hospital
Measles
Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients
Measles is a vaccine-preventable disease, which can be life-threatening in immunosuppressed children. Currently, measles vaccine is not recommended in pediatric orthotopic liver transplant recipients, because it is a…
- Trial name
- MMRinOLT (NCT01770119)
- Testing
- MMR vaccination
- Where
- Switzerland
- Volunteers
- 90 people
- Sponsor
- Klara M. Pósfay Barbe
Heart Cancer, Kidney Cancer
Cancer Development In Organ Transplant Recipients
The investigators will determine the cancer risk in organ transplant recipients compared to the general population with the help of statistical analysis.
- Conditions
- Heart Cancer, Kidney Cancer, Lung Cancer, Pancreas Cancer
- Trial name
- NCT02333279
- Where
- Switzerland
- Volunteers
- 1,800 people
- Sponsor
- University of Zurich
Liver Transplant Recipients, Liver Transplantation
Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients
The main focus of this study is to develop blood and/or urine tests that will help to detect early signs of rejection in people who have had a liver transplant.
- Trial name
- PROGENI-LI (NCT01672164)
- Where
- 6 sites in United States
- Volunteers
- 202 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplantation
A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients
To compare the safety and efficacy of Prograf® with Myfortic® to Advagraf® extended release tacrolimus with Myfortic® in de novo liver transplant recipients.
- Trial name
- NCT01018914
- Testing
- Prograf, Advagraf, Myfortic
- Where
- 3 sites in Taiwan
- Volunteers
- 44 people
- Sponsor
- Astellas Pharma Inc
Liver Transplant; Complications, Quality of Life
Starzl Network Patient Reported Outcomes
This study uses a smartphone application/web interface (RealTime Clinic; RTC) to collect patient and parent reports of a pediatric liver transplant recipient's quality of life (QOL), and examines the extent to which QOL…
- Conditions
- Liver Transplant; Complications, Quality of Life, Child Behavior, Adolescent Behavior
- Trial name
- SPaRO (NCT05241847)
- Testing
- PeLTQL delivery via electronic means
- Where
- 7 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- University of Pittsburgh
Liver Transplant Rejection
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension
This was a multicenter, open-label, active-controlled study to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 maintenance doses in de novo liver transplant recipients.
- Trial name
- CONTRAIL I (NCT03781414)
- Testing
- CFZ533, Tacrolimus - MMF - corticosteroids
- Where
- 29 sites in United States, Argentina and 8 more
- Volunteers
- 129 people
- Sponsor
- Novartis Pharmaceuticals
Cytomegalovirus Infection
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver.
- Trial name
- NCT00817908
- Where
- Canada
- Volunteers
- 131 people
- Sponsor
- University of Alberta
Transplantation, Liver
PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients
The purpose of this study is to measure the amount of MMF and tacrolimus concentration in the blood at a given time. Currently MMF is ordered as a set dose and tacrolimus is given based on body weight.
- Trial name
- NCT00178425
- Testing
- Serial blood sampling as described in protocol, Estimation of Creatinine Clearance at regular intervals
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Rochester
GI Disturbance
Myfortic Conversion Trial in OLT Recipients With GI Intolerance
Liver transplant patients often require multimodal immunosuppressive therapy to minimize their risk for rejection. In our regimen, MMF (mycophenolate mofetil) is often added to lower the side effects of the calcineurin…
- Trial name
- NCT00619216
- Testing
- Mycophenolic Acid (Myfortic)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of North Carolina, Chapel Hill
Liver Transplant
Ischemia Time and Graft Survival
Study the effect of ischemia time on patient and graft survival.
- Trial name
- NCT02521584
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- AlRefaey Kandeel
Liver Transplantation, Comorbidities and Coexisting Conditions
The Danish Comorbidity in Liver Transplant Recipients Study
Background: Liver transplantation is the only curative treatment for patients with end-stage liver disease. Short-term survival has improved due to improved surgical techniques and greater efficacy of immunosuppressive drugs.
- Trial name
- DACOLT (NCT04777032)
- Where
- 4 sites in Denmark
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
End Stage Liver Disease, Impaired Renal Function
CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment
Background: Patients undergoing liver transplantation with preexisting renal dysfunction are prone to further renal impairment with the early postoperative use of Calcineurin-inhibitors.
- Trial name
- PATRON07 (NCT00604357)
- Testing
- anti-CD 25 mAb, Sirolimus, MMF
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- University of Regensburg
Patient Survival, Graft Survival
Donor and Recipient Mismatch in Liver Transplantation
This observational study aims to investigate the impact of gender disparity between donors and recipients on long-term outcomes after liver transplantation (LT).
- Conditions
- Patient Survival, Graft Survival, Liver Disease (Alcoholic or Not), Liver Transplant Surgery
- Trial name
- DR-MM in LT (NCT07250919)
- Where
- Canada
- Volunteers
- 1,146 people
- Sponsor
- University of Jena
Hepatitis C, Hepatitis C, Chronic
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
In order to prevent organ rejection, patients receiving liver transplants currently require life-long treatment with immune system-suppressing medications to prevent the rejection of the transplanted liver.
- Conditions
- Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure
- Trial name
- A-WISH (NCT00135694)
- Testing
- calcineurin inhibitor-based immunosuppression, liver transplant, corticosteroids
- Where
- 8 sites in United States
- Volunteers
- 275 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant
The purpose of this study is to determine if the administration of a poorly-absorbable antibiotic (rifaximin) for the first three months after liver transplant will reduce the amount of fibrosis (or scarring of the liver) in…
- Trial name
- Rifaximin (NCT01603108)
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Columbia University
Orthotopic Liver Transplant
Everolimus Post Orthotopic Liver Transplant
The purpose of this study is to evaluate the efficacy of an everolimus conversion (EVR) protocol as compared to the standard tacrolimus (TAC) based protocol in liver transplant recipients, as determined by renal function…
- Trial name
- NCT01998789
- Testing
- Everolimus, Standard Tacrolimus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Tomoaki Kato